Open label study to evaluate effect, safety and tolerability of Betaferon standard dose of 250µg in patients of Chinese origin with multiple sclerosis - Trial 2014-004613-93
Access comprehensive clinical trial information for 2014-004613-93 through Pure Global AI's free database. This phase not specified trial is sponsored by Bayer HealthCare AG and is currently status unknown. The study focuses on Multiple sclerosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bayer HealthCare AG
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Any disease other than Multiple Sclerosis (MS) that could better explain the patients signs and symptoms - HIV (human immunodeficiency virus) infections - Hepatitis A - Syphilis - immunodeficiency - rheumatic disease or Sjogren syndrome - heart disease - severe depression - pregnancy or lactation - conditions interfering with Magnetic Resonance Imaging (MRI) - Gadolinium DTPA (Gadovist, contrast agent) allergy - allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance - participation in other trial
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2014-004613-93
Non-Device Trial